Limited predictive value of PD-L1 TPS for pathological response in NSCLC is not attributable to interobserver variability.

A common tumor marker shows inherent limits in predicting lung cancer treatment response—not a measurement problem, but a signal to find better biomarkers.

International study of 30 pathologists from 11 countries confirms PD-L1 TPS poor correlation with pathological response in neoadjuvant NSCLC (r=-0.16) is an intrinsic biomarker limitation, not due to interobserver variability (ICC 0.99 when scores averaged), indicating urgent need for better predictive biomarkers beyond PD-L1.

What the study was

Study design

validation_study

Category

novel_therapeutics

Maturity

clinical

Journal

Lung Cancer

A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.